source
- Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trialGilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…
- FDA issues final guidance on developing and labeling prescription drug appsThe FDA released its final guidance on Tuesday, outlining how drug sponsors should create, distribute, and label software applications that are used together with prescription medicines. The guida…